A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

Exclusion Criteria

• •Confirmed cases or history of SARS-CoV-2 infection;
• •Has a history of SARS and MERS virus infection;
• •Has fever (axillary temperature ≥37.3℃), dry cough, fatigue, nasal congestion, runny nose, sore throat, myalgia, diarrhea, shortness of breath, and dyspnea within 14 days before vaccination;
• •Positive urine pregnancy test；
• •Axillary temperature ≥37.3℃ at the day vaccinated;
• •History of severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurosis, edema, etc.) or allergies to known components of COVID-19 mRNA vaccine;
• •History or family history of convulsions, epilepsy, encephalopathy, or mental illness;
• •Suffering from congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
• •Known suffering from diseases including: acute respiratory disease (such as flu-like illness, acute cough, sore throat), severe cardiovascular disease, kidney disease, uncontrolled hypertension (systolic blood pressure \>150 mmHg, diastolic blood pressure \>90 mmHg), diabetes complications, malignant tumor, all sorts of acute illness or chronic diseases acute phase;
• •Diagnosis with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune disease;
• •Abnormal coagulation function (such as lack of coagulation factor, coagulation disorders);
• •Receiving anti-tuberculosis treatment;
• •Long-term receipt (continuous≥7 days) of glucocorticoid (reverence value for dose: amount to≥20 mg/d prednisone equivalent), except inhaled, topical, nasal, aural and ophthalmic corticosteroids, within 6 months before screening; Receipt of immunotherapy or immunosuppressant within 3 months (continuous oral or infusion for more than 14 days);
• •Receipt of live attenuated vaccine within 28 days prior to vaccination and other vaccines within 14 days prior to vaccination;
• •Receipt of blood products within 3 months prior to vaccination
• •Receipt of other study drugs within 6 months prior to vaccination;
• •Receipt of any SARS-COV-2 vaccine;
• •Other situations judged by the investigators that are not suitable for participating in this clinical trial.